Tocagen Inc. (TOCA)’s Financial Results Comparing With Sangamo Therapeutics Inc. (NASDAQ:SGMO)

Tocagen Inc. (NASDAQ:TOCA) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen Inc. 18.04M 13.86 40.19M -2.02 0.00
Sangamo Therapeutics Inc. 70.69M 12.71 62.76M -0.69 0.00

In table 1 we can see Tocagen Inc. and Sangamo Therapeutics Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Tocagen Inc. -222.78% -71.6% -46.1%
Sangamo Therapeutics Inc. -88.78% -22.1% -13.9%

Liquidity

Tocagen Inc.’s Current Ratio is 5.8 while its Quick Ratio is 5.8. On the competitive side is, Sangamo Therapeutics Inc. which has a 6.3 Current Ratio and a 6.3 Quick Ratio. Sangamo Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Tocagen Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Tocagen Inc. and Sangamo Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Tocagen Inc. 0 0 0 0.00
Sangamo Therapeutics Inc. 0 2 0 2.00

Competitively Sangamo Therapeutics Inc. has an average price target of $11, with potential upside of 25.00%.

Insider and Institutional Ownership

Institutional investors owned 31% of Tocagen Inc. shares and 66.2% of Sangamo Therapeutics Inc. shares. Insiders owned roughly 7.6% of Tocagen Inc.’s shares. On the other hand, insiders owned about 0.1% of Sangamo Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tocagen Inc. -1.47% 5.39% 3.76% 31.85% 19.68% 24%
Sangamo Therapeutics Inc. -5.58% -18.32% -20.27% -25.37% -32.09% -28.78%

For the past year Tocagen Inc. has 24% stronger performance while Sangamo Therapeutics Inc. has -28.78% weaker performance.

Summary

Sangamo Therapeutics Inc. beats on 8 of the 11 factors Tocagen Inc.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companyÂ’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in HuntingtonÂ’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.